Innate Pharma S.A. (LON:0EVI)

Innate Pharma Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 12, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	120	132	183	234	295	245
Market Cap Growth	-5.59%	-27.85%	-21.67%	-20.77%	20.59%	-38.25%
Enterprise Value	92	86	141	163	209	129
Last Close Price	1.30	1.58	2.22	2.96	3.66	3.11
PS Ratio	11.11	7.95	3.43	4.58	14.24	3.92
PB Ratio	27.28	18.11	4.07	4.87	3.27	1.75
P/TBV Ratio	27.28	18.11	4.10	5.02	5.56	2.49
EV/Sales Ratio	8.37	5.15	2.65	3.19	10.07	2.07
EV/EBITDA Ratio	-	-	-	-	-	10.86
EV/EBIT Ratio	-	-	-	-	-	133.87
EV/FCF Ratio	-2.59	-	-	-	-	-
Debt / Equity Ratio	5.25	3.51	0.77	0.78	0.41	0.12
Debt / EBITDA Ratio	-	-	-	-	-	1.33
Asset Turnover	0.10	0.14	0.33	0.25	0.09	0.20
Quick Ratio	2.08	2.50	3.51	3.21	1.67	3.64
Current Ratio	2.21	2.60	3.73	3.38	1.73	3.81
Return on Equity (ROE)	-271.37%	-162.91%	-14.28%	-71.75%	-34.53%	-0.44%
Return on Assets (ROA)	-25.92%	-22.52%	-4.23%	-4.40%	-10.40%	0.19%
Return on Capital (ROIC)	-65.68%	-48.98%	-8.42%	-8.28%	-18.30%	0.33%
Return on Capital Employed (ROCE)	-79.80%	-66.10%	-9.30%	-10.40%	-25.50%	0.40%
Earnings Yield	-32.81%	-30.93%	-3.58%	-22.02%	-15.02%	-23.41%
FCF Yield	-29.40%	-4.56%	-15.58%	-7.46%	-16.89%	-19.27%
Buyback Yield / Dilution	-4.15%	-0.74%	-1.02%	-0.12%	-0.77%	-17.97%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.